» Articles » PMID: 25976511

Fentanyls: Are We Missing the Signs? Highly Potent and on the Rise in Europe

Overview
Publisher Elsevier
Date 2015 May 16
PMID 25976511
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Fentanyl is a synthetic opioid analgesic historically used as a pain reliever and an anaesthetic. Recent concerns have arisen around the illicit use of fentanyl and its analogues in a number of European countries, linked to their high potency and associated risk of fatal overdose. Evidence has been emerging from Estonia for over a decade of entrenched patterns of fentanyl use, including injection of the drug and hundreds of overdose deaths. More recently, reports indicate that both fentanyl and 3-methylfentanyl (TMF) have been marketed as a replacement for heroin in European countries (e.g. Bulgaria, Slovakia) affected by heroin shortages. In addition, Germany, Finland and the United Kingdom, reported new outbreaks of fentanyl-related deaths. This combination of increasing mortality data alongside law enforcement intelligence suggesting both diversion and illicit production of fentanyls, prompted wider investigation using a targeted multi-source data collection exercise and analysis. This identified that in the European context, fentanyls are 'low use but high risk/harm' substances. Evidence shows that Estonia stands out as having an endemic problem, while the use of fentanyls in other European countries appears to be geographically localised. Developments in illicit supply of fentanyls reflect the complexity of Europe's contemporary drug market: manifesting illicit production and use, the diversion and misuse of medicines, and the online sale of non-controlled new psychoactive substances. Likewise effective and integrated responses will need to address fentanyl production, diversion as well as ensuring the availability of harm reduction measures to users.

Citing Articles

Ten-year analgesic utilization patterns and economic implications in Portugal.

Duarte N, Martins J, Garcia-Pedraza J, Santos M Br J Clin Pharmacol. 2024; 91(3):866-881.

PMID: 39535304 PMC: 11862792. DOI: 10.1111/bcp.16333.


Opioid-Based Haptens: Development of Immunotherapy.

Hosztafi S, Galambos A, Koteles I, Karadi D, Furst S, Al-Khrasani M Int J Mol Sci. 2024; 25(14).

PMID: 39063024 PMC: 11277321. DOI: 10.3390/ijms25147781.


Immediate release fentanyl in general practices: Mostly off-label prescribing.

Weesie Y, van Dijk L, Bouvy M, Hek K Eur J Gen Pract. 2023; 29(1):2165644.

PMID: 36695153 PMC: 9879195. DOI: 10.1080/13814788.2023.2165644.


Synthetic opioids: a review and clinical update.

Shafi A, Berry A, Sumnall H, Wood D, Tracy D Ther Adv Psychopharmacol. 2022; 12:20451253221139616.

PMID: 36532866 PMC: 9747888. DOI: 10.1177/20451253221139616.


A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects.

Celik M, Fuehrlein B Immunotargets Ther. 2022; 11:55-66.

PMID: 36199734 PMC: 9528911. DOI: 10.2147/ITT.S370435.